阿帕替尼联合替吉奥治疗耐药型进展期胃癌的疗效及安全性分析  

Analysis of the efficacy and safety of Apatinib combined with Tegafur in the treatment of drug-resistant advanced gastric cancer

作　　者：张燕[1] 张丰林[1] 刘志[1] ZHANG Yan;ZHANG Feng-lin;LIU Zhi(Department of Oncology,Maanshan People's Hospital,Anhui,Maanshan 243000,China)

机构地区：[1]马鞍山市人民医院肿瘤科,安徽马鞍山243000

出　　处：《中国医学前沿杂志（电子版）》2018年第5期82-85,共4页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

基　　金：安徽省科技计划项目(1501041160)

摘　　要：目的探究阿帕替尼联合替吉奥治疗耐药型进展期胃癌的临床效果及安全性。方法选取2017年2月至2018年2月于本院治疗的80例耐药型进展期胃癌患者为研究对象,采用随机数表法将其分为单药组和联合组,每组各40例。单药组患者采用阿帕替尼治疗,联合组患者采用阿帕替尼联合替吉奥治疗。治疗3个月后,比较两组患者的疗效、不良反应发生情况及血清基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)、血清基质金属蛋白酶-2(matrix metalloproteinase-2,MMP-2)、血清癌胚抗原(carcinoembryonic antigen,CEA)及糖类抗原19-9(carbohydrate antigen 19-9,CA19-9)的水平。结果联合组患者治疗总有效率明显高于单药组(P<0.05);治疗3个月后,两组患者血清MMP-9、MMP-2、CEA及CA19-9水平均明显下降(P<0.05),且治疗后联合组患者血清MMP-9、MMP-2、CEA及CA19-9水平均明显低于单药组(P<0.05);联合组患者不良反应发生率明显低于单药组(P<0.05)。结论在耐药型进展期胃癌的治疗中,阿帕替尼联合替吉奥较阿帕替尼单药治疗更有效,不良反应更少,安全性更高。Objective To explore the efficacy and safety of Apatinib combined with Tegafur in the treatment of drug-resistant advanced gastric cancer.Method From February 2017 to February 2018,80 patients with drug-resistant advanced gastric cancer in our hospital were selected as study objects.They were randomly divided into single drug group and combined group,40 cases in each group.Patients in single drug group were treated with Apatinib,and patients in combined group were treated with Tegafur on the basis of single drug group.After 3 months of treatment,the curative effects,adverse reactions,matrix metalloproteinase-9(MMP-9),matrix metalloproteinase-2(MMP-2),carcinoembryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9)were compared between the two groups.Result The total effective rate of treatment in combined group were significantly higher than those in single drug group(P<0.05).After 3 months of treatment,the levels of MMP-9,MMP-2,CEA and CA19-9 in the two groups were significantly decreased(P<0.05).After treatment,the levels of MMP-9,MMP-2,CEA and CA19-9 in combined group were significantly lower than those in single drug group(P<0.05).The adverse reaction rate in combined group was significantly lower than that in single drug group(P<0.05).Conclusion In the clinical treatment of drug-resistant advanced gastric cancer,Apatinib combined with Tegafur is more effective,has less adverse reactions and much safer compared to Apatinib alone.

关 键 词：阿帕替尼 替吉奥 耐药型进展期胃癌 疗效 安全性 

分 类 号：R735.2[医药卫生—肿瘤]